Abbott Laboratories (ABT)
| Market Cap | 179.53B |
| Revenue (ttm) | 40.33B |
| Net Income (ttm) | 5.63B |
| Shares Out | 1.74B |
| EPS (ttm) | 3.21 |
| PE Ratio | 32.15 |
| Forward PE | 21.46 |
| Dividend | $2.20 (2.13%) |
| Ex-Dividend Date | Jul 15, 2024 |
| Volume | 3,523,230 |
| Open | 102.70 |
| Previous Close | 103.20 |
| Day's Range | 102.70 - 103.39 |
| 52-Week Range | 89.67 - 121.64 |
| Beta | 0.74 |
| Analysts | Buy |
| Price Target | 122.30 (+18.51%) |
| Earnings Date | Jul 18, 2024 |
About ABT
Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism,... [Read more]
Financial Performance
In 2023, ABT's revenue was $40.11 billion, a decrease of -8.12% compared to the previous year's $43.65 billion. Earnings were $5.72 billion, a decrease of -17.45%.
Financial StatementsAnalyst Forecast
According to 11 analysts, the average rating for ABT stock is "Buy." The 12-month stock price forecast is $122.3, which is an increase of 18.51% from the latest price.
News
How Does The Current Fall In Abbott Stock Compare With The One During 2008 Recession?
Abbott stock (NYSE: ABT) currently trades at $105 per share, 25% below its peak level of over $140 seen in December 2021. In comparison, its peer Boston Scientific stock (NYSE: BSX) has seen a nearly ...
Abbott Hosts Conference Call for Second-Quarter Earnings
ABBOTT PARK, Ill., June 27, 2024 /PRNewswire/ -- Abbott (NYSE: ABT) will announce its second-quarter 2024 financial results on Thursday, July 18, before the market opens.
Abbott Teams Up With the National Association of Community Health Centers to Expand Access to Nutritious Food and Improve Health
Eight health centers across the U.S. participate in Innovation Incubator to find new ways to integrate healthy food into clinical care Now in its second year, the goal of the Innovation Incubator is t...
New Weight-Loss Drugs and Devices Are Coming This Week
Weight-loss breakthroughs all emerged from diabetes treatment. Meetings such as the coming American Diabetes Association are increasingly dominated by news on obesity drugs.
Abbott Declares 402nd Consecutive Quarterly Dividend
ABBOTT PARK, Ill., June 14, 2024 /PRNewswire/ -- The board of directors of Abbott (NYSE: ABT) today declared a quarterly common dividend of 55 cents per share.
FDA approves two new Abbott over-the-counter continuous glucose monitors
Abbott on Monday announced it has received FDA clearance for two new CGMs that will be available without a prescription. A CGM is a small sensor that pokes through the skin and tracks a person's gluco...
US FDA clears Abbott's continuous glucose monitors for over-the-counter use
Abbott said on Monday that the U.S. Food and Drug Administration has cleared its two continuous glucose monitoring systems for over-the-counter use.
Abbott Receives U.S. FDA Clearance for Two New Over-the-Counter Continuous Glucose Monitoring Systems
Abbott's consumer biowearable, Lingo™, is designed for general consumers who are looking to improve their overall health and wellness Libre Rio™ is designed for adults with Type 2 diabetes who do not ...
Cadrenal Therapeutics Highlights Presentation of New Trial Data at ISHLT Conference Demonstrating the Importance of Anticoagulation Quality in LVAD Patients
Tecarfarin, which recently received Orphan Drug Designation from the FDA for the prevention of thromboembolism and thrombosis in patients with an implanted mechanical circulatory support device, has t...
Calls Of The Day: Eli Lilly, UnitedHealth Group, Abbott Labs and Johnson & Johnson
The Investment Committee discuss the latest Calls of the Day.
Drugmaker Abbott India posts Q4 profit rise on higher sales
Indian drugmaker Abbott India reported a 24% rise in fourth-quarter profit on Thursday, as strong sales outpaced the impact of government pricing caps on certain medicines.
Appriss Retail Names Industry Veteran and Innovator Dean Abbott Chief Data Scientist
IRVINE, Calif.--(BUSINESS WIRE)--Appriss Retail, a leading provider of data and analytics solutions designed to reduce retail losses, decrease returns, and provide a more seamless consumer experience,...
24 Dividend Aristocrats in the stock market with the fastest-growing payouts
At a time when investors expect interest rates to remain high as the Federal Reserve seeks to keep the lid on inflation, dividend stocks may not be dominating the attention of income-seeking investors...
Abbott's Breakthrough Dissolving Stent Receives FDA Approval for Arteries Below the Knee
More than 20 million people in the U.S. are living with peripheral artery disease (PAD) yet there have been limited treatment options The first-of-its-kind Esprit™ BTK Everolimus Eluting Resorbable Sc...
Should You Pick Abbott Stock At $105 After An Upbeat Q1?
Abbott (NYSE: ABT) recently reported its Q1 results, with revenues above and earnings exceeding our expectations. The company reported revenue of $10 billion and earnings of $0.98 on a per-share and a...
Abbott Labs Stock Falls as Q2 Guidance Outweighs Earnings Beat
Shares of Abbott Laboratories (ABT) fell in intraday trading Wednesday, with second-quarter guidance seeming to outweigh first-quarter results that beat analyst estimates.
Abbott beats estimates, reports a 2.2% rise in Q1 sales
Abbott Laboratories on April 17 reported a 2.2% rise of $10 billion in its 2024 first-quarter sales which includes the impact of the anticipated decline in COVID-19 testing-related sales as compared t...
Abbott Labs Stock Is Slipping. Disappointing Guidance Trumps a Strong Quarter.
Healthcare-products firm Abbott Laboratories' first-quarter earnings beat expectations, but second-quarter guidance was light.
Abbott Labs first-quarter results top estimates amid strong medical device sales
Abbott Laboratories on Wednesday reported first-quarter sales and profit that topped expectations amid strength in its medical-device business. The healthcare-products company reported first-quarter n...
Abbott beats quarterly profit estimates on strong medical device sales
Abbott Laboratories beat Wall Street estimates for quarterly profit on Wednesday and raised the lower end of its forecast, as robust demand for medical procedures boosted sales of its devices, includi...
Abbott Reports First-Quarter 2024 Results and Raises Midpoint of Full-Year Guidance Ranges
Sales of $10.0 billion driven by strong underlying base business performance Reported sales increased 2.2 percent, which includes the impact from the anticipated decline in COVID-19 testing-related sa...
After Nearly A 20% Rise In Six Months Will Abbott Stock See Higher Levels Post Q1?
Abbott (NYSE: ABT) will report its Q1 2024 results on Wednesday, April 17. We expect the company to post revenue of $9.9 billion and earnings of $0.95 on a per share and adjusted basis, aligning with ...
US FDA approves Abbott's heart valve repair device
Abbott Laboratories said on Tuesday the U.S. FDA has approved its heart valve repair device designed for patients at risk of complications or death during open-heart surgeries.
Abbott Receives FDA Approval for TriClip™, First-of-Its-Kind Device to Repair Leaky Tricuspid Heart Valve
TriClip offers a remarkably safe, minimally invasive treatment option for patients in need of tricuspid valve repair but who are unable to withstand surgery More than 1.6 million people in the U.S. ar...
Abbott Receives FDA Clearance for Whole Blood Rapid Test to Help with Assessment of Concussion at the Patient's Bedside
The test, run on Abbott's portable i-STAT® Alinity® instrument, uses whole blood to help evaluate patients with a suspected mild traumatic brain injury (mTBI), or concussion The test produces lab-qual...